Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person alectinib resistant ALK mutants [plasma membrane]

Class:IdDefinedSet:9700560
_displayNamealectinib resistant ALK mutants [plasma membrane]
_timestamp2021-03-08 22:37:28
compartment[Compartment:876] plasma membrane
created[InstanceEdit:9700562] Rothfels, Karen, 2020-09-16
disease[Disease:1500689] cancer
hasMember
literatureReference[LiteratureReference:9700317] ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression
[LiteratureReference:9711845] Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib
[LiteratureReference:9713876] Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review
[LiteratureReference:9713917] Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
[LiteratureReference:9713982] Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden
[LiteratureReference:9715259] Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib
[LiteratureReference:9717278] Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma
modified[InstanceEdit:9714072] Rothfels, Karen, 2021-02-02
[InstanceEdit:9715308] Rothfels, Karen, 2021-02-17
[InstanceEdit:9717350] Rothfels, Karen, 2021-03-08
namealectinib resistant ALK mutants
species[Species:48887] Homo sapiens
stableIdentifier[StableIdentifier:9700586] R-HSA-9700560.1
(diseaseEntity)[EntityFunctionalStatus:9714044] loss_of_function of alectinib resistant ALK mutants [plasma membrane]
(input)[FailedReaction:9700656] alectinib resistant ALK mutants don't bind alectinib [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by alectinib resistant ALK mutants [plasma membrane] (9700560)
Follow Reactome